Medicaid Denies Nearly Half Of Requests For Hepatitis C Drugs: Study

Researchers at the University of Pennsylvania found that Medicaid turned down requests for new expensive drugs to treat hepatitis C 46 percent of the time, while private insurers barred them 10 percent and Medicare 5 percent.